These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22750845)

  • 1. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
    Price DL; Bonhaus DW; McFarland K
    Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimavanserin, a 5HT
    Yuede CM; Wallace CE; Davis TA; Gardiner WD; Hettinger JC; Edwards HM; Hendrix RD; Doherty BM; Yuede KM; Burstein ES; Cirrito JR
    J Neurochem; 2021 Mar; 156(5):658-673. PubMed ID: 33278025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pimavanserin exhibits serotonin 5-HT
    Muneta-Arrate I; Diez-Alarcia R; Horrillo I; Meana JJ
    Eur Neuropsychopharmacol; 2020 Jul; 36():83-89. PubMed ID: 32517960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can pimavanserin help patients with Parkinson disease psychosis?
    de la Cruz J; Canal C
    JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
    Snigdha S; Horiguchi M; Huang M; Li Z; Shahid M; Neill JC; Meltzer HY
    J Pharmacol Exp Ther; 2010 Feb; 332(2):622-31. PubMed ID: 19864614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
    Vanover KE; Weiner DM; Makhay M; Veinbergs I; Gardell LR; Lameh J; Del Tredici AL; Piu F; Schiffer HH; Ott TR; Burstein ES; Uldam AK; Thygesen MB; Schlienger N; Andersson CM; Son TY; Harvey SC; Powell SB; Geyer MA; Tolf BR; Brann MR; Davis RE
    J Pharmacol Exp Ther; 2006 May; 317(2):910-8. PubMed ID: 16469866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin, a 5-hydroxytryptamine 2A receptor inverse agonist, reverses prepulse inhibition deficits in the nucleus accumbens and ventral hippocampus.
    Shi M; Tang J; Yang C; Guo G; Ou H; Chen W
    Neuropharmacology; 2021 Dec; 201():108838. PubMed ID: 34666074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.